Jagsonpal Pharma Stock Jumps 12% on ₹40 Crore Buyback Plan

Shares of Jagsonpal Pharmaceuticals Ltd. surged over 12% on Thursday, March 12, 2026, after the company's board of directors approved a proposal to buy back equity shares. The announcement triggered significant investor interest, pushing the stock to its intraday high. The buyback plan, valued at ₹40 crore, reflects the management's confidence in the company's financial position and future prospects, aiming to return surplus cash to its shareholders.

Details of the Buyback Offer

The board has approved the repurchase of up to 16 lakh (1,600,000) equity shares at a price of ₹250 per share. This buyback price represents a substantial premium over the stock's trading price on the day of the announcement. The total offer size of ₹40 crore constitutes 18.35% of the company's paid-up equity share capital and free reserves. The buyback will be conducted through the tender offer route, allowing shareholders to tender their shares at the specified price. According to company filings, this is the first instance of a share buyback proposal in the company's history.

Impact on Shareholding Structure

A key aspect of this buyback is that the promoter and promoter group will not participate in the tender offer. This decision concentrates the benefits of the buyback among public shareholders. Consequently, upon completion of the buyback, the promoter and promoter group's shareholding is projected to increase from its current level of 67.2% to 68.9%. Conversely, the public shareholding is expected to decrease from 32.8% to 31.1%, assuming the full subscription of the offer. This move effectively increases the stake of the promoters without any new investment.

Market Response and Stock Performance

The market reacted positively to the news. On March 12, Jagsonpal Pharma's stock price jumped 12.4% to hit an intraday high of ₹201.5 per share. The trading volume for the day was also significantly higher than its 20-day average, indicating strong investor participation. By mid-afternoon, the stock was trading at ₹193.85, maintaining a gain of 8.5% for the day, reflecting sustained positive sentiment surrounding the corporate action.

Financial Rationale and Company Health

The decision to initiate a buyback is supported by Jagsonpal Pharma's healthy financial performance. For the fiscal year ending March 2025, the company reported sales of ₹268 crore, a notable increase from ₹208 crore in the previous year. Net profit for the same period more than doubled to ₹55 crore from ₹22 crore in FY24. The company maintains a strong balance sheet with zero debt and cash reserves of ₹128.73 crore. Furthermore, its Return on Equity (ROE) stood at a robust 28.51%, outperforming its five-year average and indicating efficient use of shareholder funds. This financial stability allows the company to return capital to shareholders without compromising its growth plans.

Procedural Framework and Next Steps

To manage the buyback process, Jagsonpal Pharmaceuticals has appointed Centrum Capital Limited, a SEBI-registered Merchant Banker, as the Manager to the Buyback. The board has also formed a "Buyback Committee" to oversee the process, including fixing the record date for determining shareholder eligibility. The proposal is now subject to approval from the shareholders, which will be sought through a postal ballot. The company will announce the timeline for the postal ballot and other subsequent steps in due course.

Analysis of the Strategic Move

A share buyback, especially at a premium, is often viewed as a positive signal by the market. It suggests that the management believes the company's shares are undervalued at their current market price. For shareholders, it provides an opportunity to exit their investment at an attractive price. The buyback also helps improve key financial ratios like Earnings Per Share (EPS) and Return on Equity (ROE) by reducing the number of outstanding shares. By using surplus cash for a buyback, the company demonstrates a commitment to efficient capital allocation and enhancing shareholder value.

Conclusion

Jagsonpal Pharma's ₹40 crore share buyback at ₹250 per share is a significant corporate action that has been well-received by the market. It underscores the company's strong financial health and its focus on rewarding shareholders. The next key event for investors will be the announcement of the record date and the shareholder vote, which will determine the final implementation of the buyback plan.